Trial Profile
Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Florquinitau F18 (Primary) ; Florbetaben F18
- Indications Alzheimer's disease; Cognition disorders; Neurodegenerative disorders
- Focus Diagnostic use
- 15 Sep 2023 Status changed from recruiting to completed.
- 10 Jan 2019 Status changed from not yet recruiting to recruiting.
- 23 Oct 2018 New trial record